Skip to Content

Efgartigimod is Safe and Effective in Previously Refractory AChR Myasthenia Gravis Patients

In this MEDtalk, Jennifer Spillane, a neurology consultant from the Queen Square, the National Hospital for Neurology, and Guys and St. Thomas’, discusses data from the UK’s Early Access to Medicine Scheme for efgartigimod, a treatment for myasthenia gravis. Jennifer highlights the data collection process, patient characteristics, treatment outcomes, and the overall efficacy and safety of efgartigimod.

Jennifer Spillane

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top